Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence

Atlas Grant Intelligence Center

Connecticut Department of Social Services (DSS)

Connecticut DSS is the lead state agency for the Rural Health Transformation Program, coordinating federally approved rural projects across population health, healthcare workforce, data and technology, and care transformation and stability. Atlas tracks only verified DSS and partner-agency opportunities and labels future RHTP rounds as Funding Watch until controlling application materials are published.

Atlas IndexFunding Organization Intelligence
Latest verification: August 30, 2026
Verified records1
Active opportunities0
Top opportunity scoreUnder review
States represented1

GeographyConnecticut

← All Healthcare Grants Funding Organization
Upcoming Atlas Opportunity Score 99/100
Verified August 30, 2026

Connecticut Department of Social Services (DSS)

Connecticut Rural Health Transformation Program — Future Funding Watch

FundingConnecticut received $154,249,105.53 for Rural Health Transformation Program Budget Period 1. This is the statewide federal award, not an individual applicant ceiling; future subaward and procurement amounts will be controlled by each published opportunity.
DeadlineFunding Watch — no next application deadline is published as of August 30, 2026. Connecticut's first OHS AI-enabled care coordination and remote patient monitoring NOFO closed July 7, 2026 at 2:00 PM ET.
Required next actionPre-position a rural Connecticut project now, but do not submit against a closed round. Map the project to one or more approved RHTP priorities — population health, workforce, data and technology, or care transformation and stability — document the rural population and baseline access gap, define measurable outcomes and sustainability, identify clinical and community partners, and monitor the Connecticut DSS RHTP page plus Connecticut procurement channels for the next controlling notice. For technology-enabled concepts, plan for interoperability, care coordination and measurable clinical impact rather than a stand-alone technology purchase.